France and Germany Suspended Use of Actos for Bladder Cancer Risk
In June 2011, Actos (Pioglitazone HCl), a leading diabetes medication globally, faced suspension in France and Germany over concerns of an increased bladder cancer risk. This action was prompted by a French epidemiological study's findings, revealing that long-term Actos users had a higher blad…